Bromotomscaline

Bromotomscaline, or 5-bromotomscaline, is a serotonin 5-HT₂ receptor modulator of the phenethylamine and scaline families related to TCB-2. It is the 5-bromo derivative tomscaline, a cyclized phenethylamine analogue of mescaline with a benzocyclobutene ring system. Bromotomscaline shows more than 10-fold higher affinities for the serotonin 5-HT_2A and 5-HT_2C receptors than tomscaline. It was developed by David E. Nichols and colleagues at Purdue University and was subsequently reported by Daniel Trachsel in 2013, who obtained the information via personal communication with Nichols in 2010. It is not a controlled substance in Canada as of 2025.